For Consumers
For Consumers
For Consumers
For Consumers
The SYNAGIS Copay Program helps lower out-of-pocket costs for eligible patients receiving SYNAGIS.
Eligible patients may get up to $6000 per calendar year to assist with out-of-pocket costs for SYNAGIS (paying as little as $0 per dose).*
SYNAGIS CONNECT® is a patient support program created by Sobi to provide individualized support to help appropriate patients get access to SYNAGIS.
Patient must be a resident of the US or Puerto Rico. Patient must be commercially insured. There are no income requirements to participate in the program. Patient is not enrolled in any government, state, or federally funded prescription program, including Medicare, Medicaid, Medigap, VA, DOD, or Tricare.
SYNAGIS is a prescription medication that is injected (50 mg and 100 mg) in certain children to help prevent serious lung disease caused by respiratory syncytial virus (RSV). You should know that SYNAGIS is used to prevent RSV, and not to treat children who already have RSV, including children:
SYNAGIS is a prescription medication that is injected (50 mg and 100 mg) in certain children to help prevent serious lung disease caused by respiratory syncytial virus (RSV). You should know that SYNAGIS is used to prevent RSV, and not to treat children who already have RSV, including children:
You Should Know: It is not known if SYNAGIS is safe and works in children who are over 24 months old when they started taking SYNAGIS.
You Should Know: SYNAGIS may cause severe allergic reactions.
You Should Know: SYNAGIS is given by injection. If the child has a problem with bleeding or bruises easily, an injection could cause a problem.
Before the child takes SYNAGIS, you should tell the child’s healthcare provider about all their medical conditions and medicines including vitamins, supplements, and herbal remedies.
The most common side effects are fever and rash.
You Should Know: These are not all the possible side effects for SYNAGIS. For more information, ask the child’s healthcare provider or review the full Prescribing Information for SYNAGIS, including Patient Information.
If you suspect that a child has experienced a side effect, call the child’s healthcare provider. You may also report side effects to Sobi North America at 1-866-773-5274 or the US Food and Drug Administration (FDA) at 1-800-FDA-1088.
AstraZeneca has transferred all rights to SYNAGIS (palivizumab) to another manufacturer, Swedish Orphan Biovitrum AB (SOBI), in January of 2019. If you need SYNAGIS support, please contact SYNAGIS CONNECT® at (866)-285-8419(866)-285-8419.